WALTHAM, Mass., Feb. 25, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:
Event: TD Cowen 45th Annual Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/Time: Tuesday, March 4, 2025 at 3:10pm ET
Location: Boston, MA
Event: Jefferies Biotech on the Beach Summit
Format: 1x1 meetings
Date: Tuesday, March 11, 2025
Location: Miami, FL
Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-march-investor-conferences-302383597.html
SOURCE Spyre Therapeutics, Inc.
For Investors: Eric McIntyre, VP of Finance and Investor Relations, Eric.mcintyre@spyre.com; For Media: Dan Budwick, 1AB, dan@1abmedia.com